Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without...
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer
About this item
Full title
Author / Creator
Garrido-Castro, Ana C , Graham, Noah , Ali, Lestat R , Herold, Christina , Desrosiers, Jennifer , Do, Khanh , Parsons, Heather , Li, Tianyu , Goel, Shom , DiLullo, Molly , Wrabel, Eileen , Williams, Amy J , Liu, Joyce F , Mittendorf, Elizabeth A , Dougan, Stephanie K , Tayob, Nabihah , Shapiro, Geoffrey I and Tolaney, Sara M
Publisher
England: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundPreclinical evidence suggests that cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors enhance antitumor immunity. We conducted a phase I trial of ribociclib (CDK4/6 inhibitor) plus spartalizumab (PD-1 inhibitor) in patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer (MBC) or advanced ovarian cancer (AOC)....
Alternative Titles
Full title
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_7bd0ffce46c74c5f81c3f53db1c6caa5
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7bd0ffce46c74c5f81c3f53db1c6caa5
Other Identifiers
ISSN
2051-1426
E-ISSN
2051-1426
DOI
10.1136/jitc-2024-010430
